Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ANTXR1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ANTXR1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ANTXR1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ANTXR1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ANTXR1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ANTXR1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ANTXR1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003153232 | Oral cavity | NEOLP | actin cytoskeleton reorganization | 28/2005 | 107/18723 | 5.43e-06 | 1.12e-04 | 28 |
GO:001095232 | Oral cavity | NEOLP | positive regulation of peptidase activity | 42/2005 | 197/18723 | 9.62e-06 | 1.82e-04 | 42 |
GO:00850291 | Oral cavity | NEOLP | extracellular matrix assembly | 12/2005 | 45/18723 | 2.17e-03 | 1.42e-02 | 12 |
GO:190199821 | Oral cavity | NEOLP | toxin transport | 10/2005 | 40/18723 | 8.10e-03 | 3.99e-02 | 10 |
GO:004586218 | Prostate | BPH | positive regulation of proteolysis | 121/3107 | 372/18723 | 2.05e-14 | 2.44e-12 | 121 |
GO:005254718 | Prostate | BPH | regulation of peptidase activity | 133/3107 | 461/18723 | 2.08e-11 | 1.43e-09 | 133 |
GO:003158910 | Prostate | BPH | cell-substrate adhesion | 110/3107 | 363/18723 | 4.64e-11 | 2.96e-09 | 110 |
GO:001095218 | Prostate | BPH | positive regulation of peptidase activity | 66/3107 | 197/18723 | 4.44e-09 | 1.66e-07 | 66 |
GO:003444616 | Prostate | BPH | substrate adhesion-dependent cell spreading | 43/3107 | 108/18723 | 7.20e-09 | 2.50e-07 | 43 |
GO:003153210 | Prostate | BPH | actin cytoskeleton reorganization | 40/3107 | 107/18723 | 1.82e-07 | 4.04e-06 | 40 |
GO:19019985 | Prostate | BPH | toxin transport | 15/3107 | 40/18723 | 1.21e-03 | 7.41e-03 | 15 |
GO:19050502 | Prostate | BPH | positive regulation of metallopeptidase activity | 6/3107 | 11/18723 | 4.49e-03 | 2.19e-02 | 6 |
GO:19050482 | Prostate | BPH | regulation of metallopeptidase activity | 10/3107 | 25/18723 | 4.57e-03 | 2.19e-02 | 10 |
GO:00430621 | Prostate | BPH | extracellular structure organization | 67/3107 | 302/18723 | 6.67e-03 | 3.00e-02 | 67 |
GO:00301981 | Prostate | BPH | extracellular matrix organization | 66/3107 | 301/18723 | 9.20e-03 | 3.92e-02 | 66 |
GO:00452291 | Prostate | BPH | external encapsulating structure organization | 66/3107 | 304/18723 | 1.15e-02 | 4.66e-02 | 66 |
GO:004586219 | Prostate | Tumor | positive regulation of proteolysis | 124/3246 | 372/18723 | 3.46e-14 | 4.31e-12 | 124 |
GO:005254719 | Prostate | Tumor | regulation of peptidase activity | 137/3246 | 461/18723 | 2.48e-11 | 1.71e-09 | 137 |
GO:003158916 | Prostate | Tumor | cell-substrate adhesion | 109/3246 | 363/18723 | 1.41e-09 | 6.71e-08 | 109 |
GO:001095219 | Prostate | Tumor | positive regulation of peptidase activity | 68/3246 | 197/18723 | 4.09e-09 | 1.66e-07 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANTXR1 | SNV | Missense_Mutation | rs201850545 | c.1130C>T | p.Thr377Met | p.T377M | Q9H6X2 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
ANTXR1 | insertion | In_Frame_Ins | novel | c.490_491insGAAGATATAATGGGGACCAAAACAGCCATGGCCCAGTCCTCA | p.Glu164delinsGlyArgTyrAsnGlyAspGlnAsnSerHisGlyProValLeuLys | p.E164delinsGRYNGDQNSHGPVLK | Q9H6X2 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANTXR1 | deletion | Frame_Shift_Del | novel | c.629delG | p.Gly210AlafsTer7 | p.G210Afs*7 | Q9H6X2 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ANTXR1 | SNV | Missense_Mutation | novel | c.1652N>T | p.Arg551Met | p.R551M | Q9H6X2 | protein_coding | deleterious_low_confidence(0.02) | benign(0.041) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
ANTXR1 | SNV | Missense_Mutation | | c.588N>A | p.Asp196Glu | p.D196E | Q9H6X2 | protein_coding | tolerated(0.75) | benign(0.036) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
ANTXR1 | SNV | Missense_Mutation | | c.589N>T | p.His197Tyr | p.H197Y | Q9H6X2 | protein_coding | tolerated(0.06) | benign(0.299) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
ANTXR1 | SNV | Missense_Mutation | novel | c.1111N>T | p.Pro371Ser | p.P371S | Q9H6X2 | protein_coding | deleterious(0.03) | probably_damaging(0.981) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ANTXR1 | SNV | Missense_Mutation | | c.308G>A | p.Arg103His | p.R103H | Q9H6X2 | protein_coding | deleterious(0.03) | probably_damaging(0.915) | TCGA-AA-3502-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ANTXR1 | SNV | Missense_Mutation | rs370351341 | c.1438C>T | p.Arg480Cys | p.R480C | Q9H6X2 | protein_coding | deleterious(0.01) | probably_damaging(0.954) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ANTXR1 | SNV | Missense_Mutation | rs149800589 | c.1316G>A | p.Arg439Gln | p.R439Q | Q9H6X2 | protein_coding | tolerated(0.27) | benign(0.354) | TCGA-AA-3844-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PD |